TY - JOUR T1 - Identification of a Potent Inverse Agonist at a Constitutively Active Mutant of Human P2Y<sub>12</sub> Receptor JF - Molecular Pharmacology JO - Mol Pharmacol SP - 338 LP - 345 DO - 10.1124/mol.105.014654 VL - 69 IS - 1 AU - Zhongren Ding AU - Soochong Kim AU - Satya P. Kunapuli Y1 - 2006/01/01 UR - http://molpharm.aspetjournals.org/content/69/1/338.abstract N2 - Human platelets express two P2Y receptors: Gq-coupled P2Y1, and Gi-coupled P2Y12. Both P2Y1 and P2Y12 are ADP receptors on human platelets and are essential for ADP-induced platelet aggregation that plays pivotal roles in thrombosis and hemostasis. Numerous constitutively active G protein-coupled receptors have been described in natural or recombinant systems, but in the P2Y receptors, to date, no constitutive activity has been reported. In our effort to identify G protein coupling domains of the human platelet ADP receptor, we constructed a chimeric hemagglutinin-tagged human P2Y12 receptor with its C terminus replaced by the corresponding part of human P2Y1 receptor and stably expressed it in Chinese hamster ovary-K1 cells. It is interesting that the chimeric P2Y12 mutant exhibited a high level of constitutive activity, as evidenced by decreased cAMP levels in the absence of agonists. The constitutive activation of the chimeric P2Y12 mutant was dramatically inhibited by pertussis toxin, a Gi inhibitor. The constitutively active P2Y12 mutant retained normal responses to 2-methylthio-ADP, with an EC50 of 0.15 ± 0.04 nM. The constitutively active P2Y12 mutant caused Akt phosphorylation that was abolished by the addition of pertussis toxin. Pharmacological evaluation of several P2Y12 antagonists revealed (E)-N-[1-[7-(hexylamino)-5-(propylthio)-3H-1,2,3-triazolo-[4,5-d]-pyrimidin-3-yl]-1,5,6-trideoxy-β-d-ribo-hept-5-enofuranuronoyl]-l-aspartic acid (AR-C78511) as a potent P2Y12 inverse agonist and 5′-adenylic acid, N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-, monoanhydride with (dichloromethylene)bis[phosphonic acid] (AR-C69931MX) as a neutral antagonist. In conclusion, this is the first report of a cell line stably expressing a constitutively active mutant of human platelet P2Y12 receptor and the identification of potent inverse agonist. ER -